Payment overview · 2025
General Payments
$133.14
7 reported records · 5 companies
Healthcare provider profile · identity verified
Vipul K Patel, MD
Allopathic & Osteopathic Physicians|General Practice · SPRINGFIELD, OH · NPI 1548233851
Verified facts
What the public records show
CMS Open Payments records show Vipul K Patel, MD received $133.14 in general payments during 2025 across 7 reported records.
PFIZER INC. accounted for 46.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 498 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.61 | 46.3% | 3 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.60 | 16.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $18.08 | 13.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.34 | 13.0% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $14.51 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $133.14 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
110 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
498 | 91 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1020 | 267 |
| Levothyroxine Sodium | Levothyroxine Sodium | 768 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 686 | 186 |
| Metoprolol Succinate | Metoprolol Succinate | 571 | 158 |
| Eliquis | Apixaban | 498 | 91 |
| Losartan Potassium | Losartan Potassium | 474 | 133 |
| Gabapentin | Gabapentin | 473 | 147 |
| Montelukast Sodium | Montelukast Sodium | 452 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 436 | 127 |
| Omeprazole | Omeprazole | 419 | 137 |
| Lisinopril | Lisinopril | 412 | 116 |
| Simvastatin | Simvastatin | 370 | 108 |
| Trazodone Hcl | Trazodone Hcl | 369 | 101 |
| Furosemide | Furosemide | 368 | 114 |
| Clopidogrel | Clopidogrel Bisulfate | 364 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 363 | 110 |
| Famotidine | Famotidine | 311 | 99 |
| Metformin Hcl Er | Metformin Hcl | 294 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 84 |
| Potassium Chloride | Potassium Chloride | 282 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 277 | 79 |
| Carvedilol | Carvedilol | 271 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 117 |
| Alendronate Sodium | Alendronate Sodium | 257 | 66 |
| Donepezil Hcl | Donepezil Hcl | 244 | 65 |
| Methylprednisolone | Methylprednisolone | 241 | 137 |
| Sertraline Hcl | Sertraline Hcl | 233 | 62 |
| Prednisone | Prednisone | 230 | 89 |
| Buspirone Hcl | Buspirone Hcl | 225 | 53 |
| Glimepiride | Glimepiride | 205 | 60 |
| Metformin Hcl | Metformin Hcl | 202 | 64 |
| Spironolactone | Spironolactone | 202 | 55 |
| Mirtazapine | Mirtazapine | 196 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 185 | 52 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 178 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 44 |
| Allopurinol | Allopurinol | 171 | 52 |
| Lovastatin | Lovastatin | 171 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 166 | 49 |
| Januvia | Sitagliptin Phosphate | 164 | 50 |
| Meloxicam | Meloxicam | 159 | 40 |
| Paroxetine Hcl | Paroxetine Hcl | 158 | 46 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 149 | 27 |
| Warfarin Sodium | Warfarin Sodium | 147 | 23 |
| Jardiance | Empagliflozin | 140 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 140 | 46 |
| Memantine Hcl | Memantine Hcl | 136 | 39 |
| Lorazepam | Lorazepam | 135 | 33 |
| Azithromycin | Azithromycin | 132 | 94 |
| Torsemide | Torsemide | 131 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 33 |
| Baclofen | Baclofen | 122 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 49 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 119 | 37 |
| Midodrine Hcl | Midodrine Hcl | 117 | 38 |
| Xarelto | Rivaroxaban | 114 | 24 |
| Farxiga | Dapagliflozin Propanediol | 110 | 26 |
| Risperidone | Risperidone | 109 | 15 |
| Divalproex Sodium | Divalproex Sodium | 108 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 107 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 24 |
| Tramadol Hcl | Tramadol Hcl | 93 | 39 |
| Silver Sulfadiazine | Silver Sulfadiazine | 91 | 41 |
| Bupropion Xl | Bupropion Hcl | 90 | 30 |
| Levetiracetam | Levetiracetam | 90 | 19 |
| Clonidine Hcl | Clonidine Hcl | 88 | 30 |
| Trulicity | Dulaglutide | 88 | 25 |
| Primidone | Primidone | 86 | 18 |
| Synthroid | Levothyroxine Sodium | 85 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 17 |
| Atenolol | Atenolol | 79 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 74 | 25 |
| Finasteride | Finasteride | 73 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 35 |
| Ipratropium Bromide | Ipratropium Bromide | 69 | 23 |
| Enulose | Lactulose | 67 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 30 |
| Meclizine Hcl | Meclizine Hcl | 64 | 32 |
| Celecoxib | Celecoxib | 62 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 22 |
| Glipizide Er | Glipizide | 56 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 56 | 24 |
| Latanoprost | Latanoprost | 55 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 40 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 22 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 53 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 39 |
| Ezetimibe | Ezetimibe | 53 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 17 |
| Novolog Flexpen | Insulin Aspart | 52 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 11 |
| Topiramate | Topiramate | 51 | 16 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Glipizide | Glipizide | 50 | 21 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 49 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 17 |
| Cilostazol | Cilostazol | 46 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 17 |
| Chlorthalidone | Chlorthalidone | 44 | 15 |
| Fenofibrate | Fenofibrate,micronized | 44 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 43 | 21 |
| Ketoconazole | Ketoconazole | 43 | 21 |
| Vraylar | Cariprazine Hcl | 42 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 41 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 41 | suppressed |
| Nystatin | Nystatin | 40 | 28 |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Repaglinide | Repaglinide | 39 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 11 |
| Promethazine Hcl | Promethazine Hcl | 37 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | 13 |
| Methocarbamol | Methocarbamol | 33 | 17 |
| Nitroglycerin | Nitroglycerin | 33 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Metolazone | Metolazone | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 29 |
| Valacyclovir | Valacyclovir Hcl | 30 | 17 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 20 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Dexamethasone | Dexamethasone | 24 | 22 |
| Estradiol | Estradiol | 24 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Nyamyc | Nystatin | 24 | 14 |
| Tyrvaya | Varenicline Tartrate | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Loperamide | Loperamide Hcl | 22 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 21 | 19 |
| Methimazole | Methimazole | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 13 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carteolol Hcl | Carteolol Hcl | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $133.14 · 7 records | PFIZER INC. | AIRSUPRA, ARISTADA, CeQur Simplicity, LYBALVI, NURTEC ODT, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error